A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine; & the I.F is 28.054] by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Succinate, an intermediate in the TCA cycle, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing ” Succinate or its analogues” may be used to treat pulmonary arterial hypertension.
Amount: $ 500*
Undisclosed information: How Succinate decreases pulmonary arterial hypertension
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for pulmonary arterial hypertension: Succinate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 2/April/2015, 10.57 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org